Hematopoietic stem cell transplantation in B- and T-cell lymphoma

Contents

1. **B0** Radioimmunotherapie bij het B-cel non-Hodgkin lymfoom.
   Samenvatting

   Introduction

   Biodrugs 2006;20:201-207

4. **B3** Preparation and evaluation of 89Zr-Zevalin for monitoring of 90Y-Zevalin biodistribution with positron emission tomography.
   Eur J Nucl Med Mol Imaging 2006;33:1337-1345

5. **B4** Biodistribution, radiation dosimetry and scouting of 90Y-ibritumomab tiuxetan therapy in patients with relapsed B-cell non-Hodgkin’s lymphoma using 89Zr-ibritumomab tiuxetan and PET.

6. **B5** No harmful impact of 90Yttrium-ibritumomab tiuxetan combined with BEAM on bone marrow microenvironment.
   ASH Annual Meeting Abstracts 2009;114:3538

7. **B6** Long-term follow up of BEAM alone or in combination with [radio]immunotherapy as conditioning for auSCT in aggressive lymphoma.
   Submitted

8. **B7** Phase III BEAM vs. 90Yttrium-ibritumomab tiuxetan [Zevalin]/BEAM with autologous hematopoietic stem cell transplantation for chemorefractory/relapsed diffuse large B-cell non-Hodgkin lymphoma.
   Appendix

9. **T6** T-cel non-Hodgkin lymfoom en coeliakie: van refractair naar EATL.
   Samenvatting

10. **T1** Novel approaches in the management of refractory celiac disease.

11. **T2** Autologous hematopoietic stem cell transplantation in refractory celiac disease with aberrant T cells.
    Blood 2007;109:2243-2249

12. **T3** Auto-SCT in refractory celiac disease type II patients unresponsive to cladribine therapy.
    Bone Marrow Transplant 2011;6:840-846

    Dig Liver Dis 2007;7:634-641

14. **T5** Disappointing outcome of allogeneic hematopoietic SCT in two EATL patients.
    Bone Marrow Transplant 2010;5:959-960